More than 40% of NOMID/CINCA patients and a less percentage of FCAS and MWS patients do not carry germ-line mutations in NLRP3. In those patients, somatic mosaicism occurring during fetal development may explain the variation in disease onset (59); this mechanism can only be demonstrated by cell cloning and next-generation sequencing (NGS). Here, NLRP3 is linked to CINCA syndrome.